Gozde Kubra Yardimci
Gozde had a rheumatology training at the Hacettepe University Faculty of Medicine, Ankara, Turkey. She completed her Vasculitis Clinical Research Consortium (VCRC)- Vasculitis Foundation (VF) Fellowship at the Mount Sinai Hospital, under the supervision of Prof. Christian Pagnoux. Her major interests are vasculitis, Pregnancy & Rheumatic diseases. Gozde is also a member of the Hacettepe Society of Rheumatology (HSR), Turkish Society of Rheumatology (TSR) and the Vasculitis Clinical Research Consortium (VCRC). Gozde is a member of the EMEUNET Newsletter sub-committee.
| Poster 0329 | Friday, 13th June 2025 09:30 CEST Clinical Poster Tours: Treatment aspects of small vessels vasculitis and Behcet’s disease Author: M. Shiomi (Japan) Title: Recent glucocorticoid-sparing strategies lead to better prognosis for ANCA-associated vasculitis: Insights from the multicenter REVEAL cohort study  A real-world multicenter study of 460 AAV patients from the REVEAL cohort found that recent glucocorticoid-sparing strategies, increasingly adopted after 2019, were associated with improved prognosis. Although MPA showed the highest mortality, reduced glucocorticoid exposure correlated with better survival outcomes across all AAV subtypes. |
| Oral 0172| Thursday, 12th June 2025 10:30 CEST •Clinical Abstract Sessions: Drop the ANCA, save that vessel! Author: E. Fiorin (Italy) Title: IgG anti-pentraxin 3 autoantibodies: A novel diagnostic tool for differentiating EGPA from eosinophilic asthma and chronic rhinosinusitis with nasal polyps This study reveals a novel association between anti-PTX3 autoantibodies and EGPA, highlighting their potential as a promising biomarker to distinguish EGPA from CRSwNP. Detected in 35% of EGPA patients compared to less than 5% of controls, anti-PTX3 demonstrated strong diagnostic value, independent of ANCA status. These findings support its role in the early identification of patients in the prodromal phase of EGPA, enabling earlier diagnosis and more targeted treatment decisions. |
| Oral 0189 | Thursday, 12th June 2025, 10:30 CEST •Clinical Abstract Sessions: IGG4 and other diseases Author: López-Gutiérrez, F (Spain) Title: Safety and efficacy of Inebilizumab in IgG4-Related Disease across various participant demographics: Subgroup analysis from the MITIGATE study This trial demonstrated that inebilizumab significantly reduced IgG4-RD flares and improved remission rates across various participant demographics. Subgroup analyses by age, sex, and race consistently showed clinical benefit, with similar hazard and odds ratios across groups. With a favorable safety profile, these findings highlight inebilizumab as a promising and broadly effective treatment option for patients with IgG4-related disease. |
| Oral 0058 | Wednesday, 11th June 2025, 16:30 CEST Clinical Abstract Sessions: Clinical and Treatment Aspects in Large Vessel Vasculitis Author: Klapa, S (Germany) Title: Effects of clofutriben, A Selective 11ß-hydroxysteroid dehydrogenase type 1 Inhibitor, on efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica In this first placebo-controlled trial of co-administration of clofutriben in PMR, this selective 11β-HSD1 inhibitor reduced glucocorticoid-related toxicity—including adverse effects on bone, lipid metabolism, and cardiovascular markers—while maintaining anti-inflammatory efficacy. These findings suggest that clofutriben may optimize the benefit-risk profile of glucocorticoid therapy in polymyalgia rheumatica. |
| Poster 0020 | •Wednesday, 11th June 2025, 15:30 CEST Clinical Poster Tours: A Very Varied Vasculitis Visit Author: L. Ioria (Italy) Title: Rheumatoid factor (RF) in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A red flag for vasculitis relapse This study identifies rheumatoid factor (RF) positivity at diagnosis as a key predictor of vasculitic relapse in EGPA. Using a random forest model, RF presence showed the highest importance in predicting relapse, outperforming other factors like ANCA and age at disease onset highlighting the importance of considering early RF testing to guide personalized management and improve outcomes in EGPA patients. |